| abstract |
Novel ergoline compounds of the following formula are described:n wherein R 1 is ethyl, n-propyl, or allyl; Y is O, S, SO, or SO 2 ; X is hydrogen, chloro, or bromo; the dotted line represents the optional presence of a double bond; and the pharmaceutically-acceptable acid addition salts thereof. The compounds are useful to inhibit prolactin secretion or to treat Parkinson's syndrome. |